Detalhe da pesquisa
1.
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia.
N Engl J Med
; 389(1): 33-44, 2023 Jul 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37407001
2.
Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.
N Engl J Med
; 386(26): 2482-2494, 2022 06 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-35657079
3.
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.
N Engl J Med
; 386(7): 640-654, 2022 02 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-34891224
4.
Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma.
Blood
; 141(19): 2307-2315, 2023 05 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36821768
5.
Genomic landscape of patients in a phase II study of zanubrutinib in ibrutinib- and/or acalabrutinib-intolerant patients with B-cell malignancies.
Haematologica
; 2024 Jan 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38268449
6.
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.
N Engl J Med
; 382(14): 1331-1342, 2020 04 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32242358
7.
A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma.
Blood
; 137(5): 600-609, 2021 02 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33538797
8.
Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy.
Blood
; 137(20): 2817-2826, 2021 05 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-33259589
9.
Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial.
Lancet Oncol
; 23(8): 1031-1043, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35810754
10.
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.
Lancet
; 397(10277): 892-901, 2021 03 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33676628
11.
Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphoma.
Blood
; 136(23): 2628-2637, 2020 12 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32785666
12.
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial.
Haematologica
; 107(9): 2108-2120, 2022 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35021599
13.
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial.
Lancet
; 395(10232): 1278-1291, 2020 04 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-32305093
14.
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.
N Engl J Med
; 379(10): 934-947, 2018 09 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30184451
15.
Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia.
Blood
; 133(26): 2765-2775, 2019 06 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-30862645
16.
Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib.
Blood
; 133(7): 676-687, 2019 02 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-30510081
17.
Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study.
Ann Hematol
; 100(7): 1733-1742, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-34018029
18.
A phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed or relapsed/refractory multiple myeloma: Final analysis of second dose-expansion cohort.
Am J Hematol
; 96(4): 428-435, 2021 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33421178
19.
The combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphoma.
Br J Haematol
; 189(4): 650-660, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32180219
20.
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.
N Engl J Med
; 377(26): 2531-2544, 2017 12 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-29226797